BP1.4979

Phase 2Small molecule

BBioprojet

BP1.4979 is one of 120 small molecule programs targeting Eating Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

119

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eating DisorderActive, not recruiting

Essential TremorActive, not recruiting

Smoking CessationActive, not recruiting

Premature EjaculationActive, not recruiting

Eating DisorderPhase 2

Active, not recruiting

Essential TremorPhase 2

Active, not recruiting

Smoking CessationPhase 2

Active, not recruiting

Premature EjaculationPhase 2

Active, not recruiting

Competition

Competitive Landscape

154 competitors in Smoking Cessation

#DrugCompanyPhaseTrials

Wellbutrin

GSK

Phase 3

5 2

Chantix

Pfizer

Phase 3

3 3

Ozempic

Novo Nordisk

Phase 3

2 4

Topamax

WWim Janssens

Phase 3

3 5

Rimonabant

Sanofi

Phase 3

5 6

Lopid

Pfizer

Phase 2

1 7

Pharmacotherapy

UUniversity of Pittsburgh

Phase 3

1 8

Standard Treatment

Boehringer Ingelheim

Phase 3

1 9

Zocor

OOrganon and Co

Phase 2

1 10

Selincro

IIndivior Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Premature Ejaculation

NCT07047404

Phase 2Recruiting

Essential Tremor

NCT07074002

Clinical

Trials by Indication[1]

Smoking Cessation1 trial

Efficacy and Safety of BP1.4979 in Smoking Cessation

Completed·BBioprojet·Phase 2·NCT01785147·219 enrolled

Eating Disorder1 trial

Pilot Study on BP1.4979 Effect on Binge Eating Disorders

Completed·BBioprojet·Phase 2·NCT05118906·67 enrolled

Premature Ejaculation1 trial

Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation

Recruiting·BBioprojet·Phase 2·NCT07047404·60 enrolled

Essential Tremor1 trial

Proof of Concept Study on BP1.4979 Effect on Essential Tremor

Recruiting·BBioprojet·Phase 2·NCT07074002·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for BP1.4979. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BP1.4979 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BP1.4979. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bioprojet company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBioprojet

BP1.4979

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Smoking Cessation1 trial

Eating Disorder1 trial

Premature Ejaculation1 trial

Essential Tremor1 trial

References

Drug Info

Quick Facts

Related News